Company intelligence / Profile preview
Liposeuticals
- Ownership
- Private
- Development stage
- Other
01
Overview
Liposeuticals has completed full GLP animal toxicology studies and safety pharmacology studies on its sugar-lipid polymer technology. The company has demonstrated bioequivalence of its formulations versus existing marketed emulsion-based preparations and validated complete solubilization of organic APIs with >90% reduction in lipid content compared to currently marketed products. A drug master file (DMF) has been filed with the FDA under review[3].
- Therapeutic areas
- OncologyOtherInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Beyond the preview
Go deeper on Liposeuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Liposeuticals.